Nestec S.a.

Societe Des Produits Nestle S.a.

Biogaia Ab

Institut National De La Recherche Agronomique

Clara Lucia Garcia-Rodenas

Valerie Petit

Monique Julita

Annick Mercenier

Olivier Ballevre

Sophie Helene Nutten

Guenolee Prioult

Florence Rochat

Michael Affolter

Marco Enrico Turini

Jose Manuel Ramos Nieves

Myriam Sandrine Steinmann

Elizabeth Offord Cavin

Chandrasekhara Reddy Mallangi

Bernard Berger

Eileen C Fuchs

Gabriela Bergonzelli Degonda

Helen Gillian Anantharaman

Catherine Ngom-Bru

Norbert Sprenger

Ferdinand Haschke

Sagar Thakkar

Anne Donnet-Hughes

Gabriela Bergonzelli

Melissa Lepage

Yves Guigoz

Isabelle Bureau-Franz

Francois Couzy

Irène Corthesy-Theulaz

Christine Cherbut

Francis Foata

Sami Damak

Laurent Ameye

Paul-Andre Finot

Timothy James Wooster

Enea Rezzonico

Kristel Reiffers-Magnani

Peter D Leathwood

Bernard Beaufrere

Martial Dangin

Paul-André Finot

Tara Neville

Jean-Claude Maire

Andreas Rytz

Jane Mea M Natividad

Claire Laurence Lucie Marie Boulange

Kurt Ornstein

Stephanie Viguet-Carrin

Euridice Castaneda Gutierrez

Matthias Hoppler

Anne Net-Hughes

Stéphanie Viguet-Carrin

Valérie Petit

Degonda Gabriela Bergonzelli

Guénolée Prioult

Kornél Nagy

Jane Mea M NATÎVIDAD

José Manuel Ramos Nieves

Peter Leathwood

Sophie Nutten

Kim-Anne Le

This invention relates to nutritional compositions comprising at least one N-acetylated oligosaccharide for use in the promotion of the development and/or of the growth of the intestinal muscles, in the promotion of contractile capacity and/or the motility in the intestine, in the promotion of enteral feeding tolerance and in prevention and/or treatment of small intestinal bacterial overgrowth (SIBO) in an infant, a young child or, when the composition is a growing-up milk, in a child.

Compositions for use in the promotion of intestinal muscle growth and development and associated intestinal motility

The present invention relates to nutritional compositions comprising 2'-Fucosyllactose (2′FL) for use in improving the gastrointestinal barrier. In particular, the present invention relates to improving gastrointestinal barrier in an infant, a young child or children aged above 3 years to 8 years.

Nutritional composition comprising 2'-Fucosyllactose (2′ FL) to improve the gastrointestinal barrier

This invention relates to compositions for use in the promotion of the development and/or of the growth of the surface area of the small intestine and in the associated improvement of the digestive capacity in an infant or in a young child.

Compositions comprising at least one n-acetylated and at least one fucosylated oligosaccharide for use in the promotion of digestive capacity in infants and young children

A maternal composition wherein said maternal composition is specifically formulated for a woman who has given birth prematurely or who is at risk of giving birth prematurely.

Maternal supplement

The present invention relates to a preterm human milk fortifier composition, more specifically to a preterm milk fortifier composition providing one or more specific nutrient in amounts that are missing in human milk of women who gave birth to a preterm infant. In particular the present invention relates to a fortifier composition designed for infants as a supplement to preterm human breast milk at the time the infant leaves the hospital (discharge) and after. The invention furthermore relates to the use of said preterm human milk fortifier composition.

Human milk fortifier composition

The invention concernsfor use in the prevention or treatment of microbiota dysbiosis, in particular, decreased levels of Actinobacteria and increased levels of Proteobacteria, in young mammals and in the prevention or treatment of disorders associated therewith. The microbiota dysbiosis may have been cause by numerous factors including being born by caesarean section, exposure to antibiotics in utero or after birth, or, parenteral feeding, hospitalizing, psychological stress or by gastrointestinal dysfunctions. The disorders that may be treated or prevented by preventing or treating microbiota dysbiosis include propensity to infection, allergy, type I diabetes mellitus, insulin resistance, type 2 diabetes, celiac disease, peripheral and central adiposity, obesity, necrotizing enterocolitis, inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, and functional gastrointestinal disorders such as IBS, functional diarrhea, functional constipation, recurrent abdominal pain, and dyspepsia.

Use offor recovery of microbiota dysbiosis in early life

The present invention generally relates to the field of preventing and/or treating inflammatory and infectious disorders, in particular by boosting the endogenous antimicrobial defences. One embodiment of the present invention is the use of non-replicatingLa1 NCC533 (deposit number CNCM I-1225) for use in the treatment or prevention of disorders related to the immune system including infections.

La1 NCC533 (CNCM I-1225) and immune disorders

The present invention generally relates to the field of probiotics, and in particular to preventing and/or treating inflammatory and infectious disorders, for example by boosting the endogenous antimicrobial defences. One embodiment of the present invention is a composition comprising a combination of(La1, NCC 533, deposit number CNCM I-1225) andNCC2705 (deposit number CNCM I-2618). This composition may be used in the treatment or prevention of disorders related to the immune system including infections.

[object Object]

The invention discloses a composition comprising a mixture of oligosaccharides, said mixture containing at least one N-acetylated oligosaccharide, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, for use in the promotion magnesium absorption and/or magnesium retention. The composition preferably further comprises at least one long chain polyunsaturated fatty acid and/or at least one probiotic. This composition is particularly adapted for use in infants notably preterm infants.

Composition for use in the promotion of magnesium absorption and/or magnesium retention

The invention discloses a composition comprising at least one long chain polyunsaturated fatty acid, at least one probiotic and a mixture of oligosaccharides, said mixture containing at least one N-acetylated oligosaccharide, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease. Said bone disease is in particular osteomalacia, rickets, osteopenia or osteoporosis. Preferably the composition is a nutritional composition.

Composition for use in the promotion of healthy bone growth and/or in the treatment of bone disease

The invention discloses a composition comprising at least one long chain polyunsaturated fatty acid, at least one probiotic and a mixture of oligosaccharides, said mixture containing at least one of lacto-N-neotetraose (LNnT) and lacto-N-tetraose (LNT), at least one N-acetylated oligosaccharide different from LNnT and LNT, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, for use in increasing insulin sensitivity and/or reducing insulin resistance. This composition optionally further comprises 2'-fucosyllactose (FL). This composition is particularly adapted for use in infants who were born preterm and/or who experienced IUGR, in pregnant women suffering from gestational diabetes and in children, adolescents, and adults suffering from insulin resistance and/or type II diabetes.

Composition for use in increasing insulin sensitivity and/or reducing insulin resistance

The present invention relates to non-replicating probiotic micro-organisms and their health benefits. For example, the present invention relates to compositions comprising non-replicating probiotic micro-organisms for use in the treatment of prevention of upper respiratory tract infections and/or their symptoms. Embodiments of the present invention provide means to help parents to protect their children from such upper respiratory tract infections.

Non-replicating probiotic micro-organisms protect against upper respiratory tract infections

Growing community of inventors

Forel, Switzerland

Clara Lucia Garcia-Rodenas